Fig. 5.
SNAs demonstrate immunomodulatory properties in vivo. (A) [Ag]IS-SNAs enhance tumor clearance. Mice were inoculated with 2 × 106 E.G7-OVA cells into the right flank on day 0, then treated as indicated with one treatment on days 3, 5, and 7. (B) Tumor growth curves (n = 11 mice per group, error bars show mean ± SEM) and (C) corresponding survival endpoints. (D) IR-SNAs show enhanced treatment of liver fibrosis in mice with NASH. STAM mice were treated every other day from 6 to 9 wk of age. At 9 wk, the liver was collected and processed for (E) fibrosis score by Sirius Red staining and (F) nonalcoholic fatty liver disease activity (NAS) score by H&E (n = 8 mice per group; points show mean ± SEM).